Key Findings
- Vision loss in CLN3-Batten disease may begin earlier—and in different cells—than scientists previously realized.
- A new human retina model gives researchers an unprecedented view of how the disease damages the eye.
- A promising experimental treatment helped protect the retina in preclinical studies.
- The research could accelerate the search for treatments that preserve vision and improve the quality of life for children with CLN3-Batten disease.
Researchers have developed a new way to study CLN3-Batten disease, a rare, inherited condition that causes early vision loss in children followed by progressive neurological decline. Their findings offer new insight into how the disease begins and point to a promising path for treatment
Vision loss is often the first and most life-altering symptom for children with the disease, affecting their ability to read, learn, and navigate the world independently, often years before other neurological symptoms appear
A model that mimics the human retina
Studying CLN3-Batten disease has been challenging because the earliest damage occurs deep within the retina, a part of the eye that is difficult for researchers to access. To overcome this, researchers at University of Rochester Medicine have created a 3D human stem cell-derived retina model that closely mimics how key parts of the eye work together, specifically, the interaction between light-sensing photoreceptors and support cells called the retinal pigment epithelium (RPE)
“Although molecular and cellular changes associated with the disease have been shown in other models, this retina model captures the earliest and most consistent pathology seen in patients, including photoreceptor outer segment loss and degeneration,” said Ruchira Singh, PhD, an associate professor in the URochester Medicine Flaum Eye Institute, and lead author of the study, which appears in Science Translational Medicine
A new understanding of how damage begins
While CLN3-Batten disease has long been considered a neurodegenerative disorder, meaning researchers believed the primary damage occurred in neurons like photoreceptors, this new study reveals a more complex picture
Using their model, the team showed that damage to RPE support cells alone can trigger photoreceptor degeneration. This suggests that the disease may begin when these support cells do not function properly. “Our data shows that primary RPE dysfunction is sufficient to instigate photoreceptor degeneration,” Singh said. “This may help explain why vision loss is one of the earliest symptoms in CLN3-Batten disease.”
A key biological clue and a potential treatment
The researchers also identified a critical molecular problem in CLN3-Batten disease cells: reduced levels of an enzyme called acid ceramidase (AC), which helps regulate fats (lipids) inside cells. When AC levels drop, harmful lipid imbalances develop, contributing to retinal damage
To address this, the team tested a potential treatment, recombinant human acid ceramidase (rhAC), in both lab-grown retinas and a large-animal model of the disease. The results were encouraging, and the therapy improved cellular health and reduced signs of retinal degeneration. “rhAC is a strong therapeutic candidate because it restores enzyme activity in diseased cells without affecting healthy ones,” said Singh
What this means for future treatments
Several therapies for CLN3 disease are already in development, including gene therapies and drugs targeting lipid metabolism. This new research could help improve those approaches by highlighting the importance of treating both photoreceptors and their supporting cells
The new retina model also provides a powerful tool for testing potential therapies for CLN3-Batten disease in a system that closely reflects human disease and may also model other retinal diseases that affect the photoreceptor-RPE tissue in the eye
While the results are promising, more research is needed before this approach can be tested in patients. Future studies will focus on long-term safety and effectiveness, as well as whether this strategy could help address other aspects of the disease beyond vision loss
Additional co-authors include Jimin Han, Nathaniel Foley, Sonal Dalvi, Janet A. H. Tang, Fesahat Emira-Dogrul, Amit Chatterjee1-3, Lal Krishan Kumar, Chad A. Galloway, Ajay Kumar Singh, Leah Grego, Yashoda Subedi, Kevin Ling, Alison Heffer, Xingxuan He, Vamsi K. Gullapalli, Brent Johnson, Richard T. Libby, Danielle S. W. Benoit, and Jennifer J. Hunter with the University of Rochester; Anthony Cook with the University of Tasmania; Vera Bonilha with the Cleveland Clinic; and Edward Schuchman with the Icahn School of Medicine. The research was funded by the National Eye Institute, the ForeBatten Foundation, and the Mangurian Foundation.
